Eric Sjoberg

Dr. Sjoberg has more than 25 years of experience in biotechnology with expertise in pharmacology, biochemistry, molecular biology, and assay development. Prior to cofounding Mablytics, Dr. Sjoberg cofounded OrPhi Therapeutics, a pharmacological chaperone company focused on rare disease, where he served as vice president, preclinical development. Prior to OrPhi Therapeutics, he held positions of increasing responsibility including director, preclinical biology, at Amicus Therapeutics, where he helped establish a new lab focused on therapeutic protein discovery and production. He was also instrumental in leading the discovery efforts using pharmacological chaperones for 3 different preclinical programs. Dr. Sjoberg has published 17 peer-reviewed scientific articles, has been the principal investigator or co-investigator on 8 SBIR or private foundation grants, and is the inventor on 7 issued patents in the biochemistry field. Dr. Sjoberg received his B.S. and Ph.D. from the University of California, San Diego, and did his postdoctoral research at Cytel Corporation under the guidance of James Paulson.